Literature DB >> 25514096

PharmGKB summary: very important pharmacogene information for CFTR.

Ellen M McDonagh1, John P Clancy, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25514096      PMCID： PMC4336773          DOI： 10.1097/FPC.0000000000000112

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  77 in total

Review 1.  Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.

Authors:  Bob Lubamba; Barbara Dhooghe; Sabrina Noel; Teresinha Leal
Journal:  Clin Biochem       Date:  2012-06-12       Impact factor: 3.281

2.  Personalized medicine in cystic fibrosis: dawning of a new era.

Authors:  John P Clancy; Manu Jain
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

3.  The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective.

Authors:  Zoe Louise Saynor; Alan Robert Barker; Patrick John Oades; Craig Anthony Williams
Journal:  Pediatr Phys Ther       Date:  2014       Impact factor: 3.049

4.  Improvement in bronchiectasis on CT imaging in a pediatric patient with cystic fibrosis on ivacaftor therapy.

Authors:  Don Hayes; Frederick R Long; Karen S McCoy; Shahid I Sheikh
Journal:  Respiration       Date:  2014-08-21       Impact factor: 3.580

5.  Resolution of cystic fibrosis-related diabetes with ivacaftor therapy.

Authors:  Don Hayes; Karen S McCoy; Shahid I Sheikh
Journal:  Am J Respir Crit Care Med       Date:  2014-09-01       Impact factor: 21.405

6.  Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).

Authors:  Edward F McKone; Drucy Borowitz; Pavel Drevinek; Matthias Griese; Michael W Konstan; Claire Wainwright; Felix Ratjen; Isabelle Sermet-Gaudelus; Barry Plant; Anne Munck; Ying Jiang; Geoffrey Gilmartin; Jane C Davies
Journal:  Lancet Respir Med       Date:  2014-10-09       Impact factor: 30.700

7.  Antibacterial properties of the CFTR potentiator ivacaftor.

Authors:  Leah R Reznikov; Mahmoud H Abou Alaiwa; Cassie L Dohrn; Nick D Gansemer; Daniel J Diekema; David A Stoltz; Michael J Welsh
Journal:  J Cyst Fibros       Date:  2014-03-05       Impact factor: 5.482

8.  Ivacaftor potentiation of multiple CFTR channels with gating mutations.

Authors:  Haihui Yu; Bill Burton; Chien-Jung Huang; Jennings Worley; Dong Cao; James P Johnson; Art Urrutia; John Joubran; Sheila Seepersaud; Katherine Sussky; Beth J Hoffman; Fredrick Van Goor
Journal:  J Cyst Fibros       Date:  2012-01-30       Impact factor: 5.482

9.  Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.

Authors:  Z Kopeikin; Z Yuksek; H-Y Yang; S G Bompadre
Journal:  J Cyst Fibros       Date:  2014-05-03       Impact factor: 5.482

10.  Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay.

Authors:  Laura Lentini; Raffaella Melfi; Aldo Di Leonardo; Angelo Spinello; Giampaolo Barone; Andrea Pace; Antonio Palumbo Piccionello; Ivana Pibiri
Journal:  Mol Pharm       Date:  2014-02-07       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.